Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Thioridazine hydrochloride
Drug ID BADD_D02201
Description A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618). Thioridazine was withdrawn worldwide in 2005 due to its association with cardiac arrythmias.
Indications and Usage For the treatment of schizophrenia and generalized anxiety disorder.
Marketing Status approved; withdrawn
ATC Code N05AC02
DrugBank ID DB00679
KEGG ID D00798
MeSH ID D013881
PubChem ID 66062
TTD Drug ID D0U1OE
NDC Product Code 51079-566; 51079-567; 0378-0612; 46204-0006; 53489-500; 0378-0614; 51927-1928; 53489-148; 53489-150; 61876-0075; 0378-0618; 51079-565; 53489-149; 0378-0616; 51079-580
UNII 4WCI67NK8M
Synonyms Thioridazine | Thioridazine Hydrochloride | Thioridazine HCL | Thioridazine-Neurazpharm | Thioridazine Neurazpharm | ThioridazineNeurazpharm | Thiozine | Aldazine | Meleril | Mellaril | Melleril | Melleryl | Melleretten | Melzine | Rideril | Sonapax | Apo-Thioridazine | Apo Thioridazine | ApoThioridazine
Chemical Information
Molecular Formula C21H27ClN2S2
CAS Registry Number 130-61-0
SMILES CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Headache17.14.01.001--
Hyperpyrexia08.05.02.002--Not Available
Hypotension24.06.03.002--
Ileus paralytic07.02.05.001--Not Available
Incontinence20.02.02.004; 17.05.01.006; 07.01.06.011--Not Available
Jaundice01.06.04.004; 23.03.03.030; 09.01.01.004--Not Available
Laryngeal oedema10.01.05.003; 23.04.01.005; 22.04.02.001--
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.008--
Leukopenia01.02.02.001--Not Available
Menstruation irregular21.01.01.005; 05.05.01.008--
Miosis17.02.11.002; 06.05.03.003--Not Available
Muscle rigidity17.05.02.005; 15.05.04.001--Not Available
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
Oculogyric crisis17.01.03.002; 06.05.02.002--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Opisthotonus17.01.03.005--Not Available
Pallor24.03.04.001; 08.01.03.032; 23.03.03.031--Not Available
Pancytopenia01.03.03.003--Not Available
Parkinsonism17.01.05.003--Not Available
Parotid gland enlargement07.06.03.001--Not Available
Photosensitivity reaction23.03.09.003--
Pregnancy test false positive13.10.05.003--Not Available
Psychomotor hyperactivity19.11.02.003; 17.01.02.011--Not Available
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Restlessness19.11.02.002; 17.02.05.021--
Somnolence17.02.04.006; 19.02.05.003--
Sudden death08.04.01.003; 02.03.04.013--
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages